Pasar al contenido principal

MATRICES MIMETIZANTES DE LA INFECCION

PID2021-124986OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Designing polyphosphazene derivatives for gene delivery in glioblastoma treatment

  • García Mazás, Carla
  • Bozzato, Elia
  • Araujo Fernández, Jhonathan Angel
  • Quattrini, Federico
  • Preat, Veronique
  • Sánchez Piñón, Laura
  • Csaba, Noemi Stefania
  • García Fuentes, Marcos
Gene therapy presents promising opportunities to target critical pathways in complex cancers like glioblastoma multiforme, though it necessitates the use of efficient delivery vectors. Polyphosphazenes (PPZs) are highly flexible materials that lead to biodegradable, high-performance materials in various applications, including gene delivery. In this work, we synthesized various PPZ derivatives, incorporating primary amines, secondary amines, hydrophilic, and hydrophobic groups, and evaluated their gene transfection capabilities in combination with an anionic polyphosphazene (6MHA-PPZ) that acts as a charge quencher and transfection enhancer. Combining 6MHA-PPZ with a hydrophobic polymer demonstrated the highest gene delivery efficiency and safety, significantly surpassing previous benchmarks. Using these optimized nanoparticles, we delivered a BMP4-expressing plasmid (pBMP4) in glioblastoma models. The pBMP4 nanoparticles, when combined with the chemotherapeutic agent temozolomide (Tz), resulted in significant reductions in tumor volume, improved survival rates in preclinical models, and normalized the expression of drug resistance markers, providing a synergistic antitumoral effect with Tz. This study highlights the potential of PPZ-based nanoparticles for gene delivery and suggests that the combination of pBMP4-NPs and Tz could offer a promising therapeutic strategy for treating glioblastoma.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Transcript‑activated matrices with optimized mRNA designs to direct chondroblastic lineage commitment

  • Rilo Álvarez, Héctor
  • Martínez Ledo, Adriana
  • López Peña, Mónica
  • Muñoz Guzón, Fernando María
  • Vidal Figueroa, Anxo
  • García Fuentes, Marcos
New strategies are required to modulate early chondroblastic differentiation in a controlled and transient manner, a key challenge in cartilage tissue engineering. Transcript‑Activated Matrices (TAMs), formed by embedding mRNA within biomaterial scaffolds, offer a promising platform for directing lineage specification. Here, we optimized TAM performance by engineering two key transcript features, directly transcribed poly(A) tails and chemically modified nucleotides, to enhance expression magnitude and persistence. Using SOX9 as a model transcription factor, we evaluated how these structural modifications influence chondroblastic programming. Template-encoded poly(A) tails markedly increased transcript output, and incorporation of chemically modified nucleotides further enhanced the magnitude and persistence of SOX9 expression. Optimized SOX9‑TAMs increased SOX9 expression by approximately 5 to 40-fold in 3D cultures and promoted early chondroblastic programming, as indicated by increased ACAN (∼20‑fold) and reduced hypertrophic signaling (e.g., decreased COL‑X). In a rabbit cartilage defect model, TAM implantation induced a consistent pro‑chondroblastic transcriptional signature (e.g., SOX9 ∼50‑fold, COL-II ∼20‑fold vs. controls), despite modest early histological changes. Together, these findings reveal that rational transcript design substantially improves TAM performance and provides precise control over early chondroblastic fate. This transcript‑engineered platform represents a promising approach for directing differentiation programs in tissue engineering applications.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Polyphosphazene-Based Nanotherapeutics

  • Gutiérrez Gutiérrez, Sara
  • Mellid Carballal, Rocío
  • Csaba, Noemi Stefania
  • García Fuentes, Marcos
Poly(organo)phosphazenes (PPZs) are increasingly recognized as versatile biomaterials for drug delivery applications in nanomedicine. Their unique hybrid structure—featuring an inorganic backbone and highly tunable organic side chains—confers exceptional biocompatibility and adaptability. Through precise synthetic methodologies, PPZs can be engineered to exhibit a wide spectrum of functional properties, including the formation of multifunctional nanostructures tailored for specific therapeutic needs. These attributes enable PPZs to address several critical challenges associated with conventional drug delivery systems, such as poor pharmacokinetics and pharmacodynamics. By modulating solubility profiles, enhancing drug stability, enabling targeted delivery, and supporting controlled release, PPZs offer a robust platform for improving therapeutic efficacy and patient outcomes. This review explores the fundamental chemistry, biopharmaceutical characteristics, and biomedical applications of PPZs, particularly emphasizing their role in zero-dimensional nanotherapeutic systems, including various nanoparticle formulations. PPZ-based nanotherapeutics are further examined based on their drug-loading mechanisms, which include electrostatic complexation in polyelectrolytic systems, self-assembly in amphiphilic constructs, and covalent conjugation with active pharmaceutical agents. Together, these strategies underscore the potential of PPZs as a next-generation material for advanced drug delivery platforms.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Viral protein nanoparticles (Part 1): Pharmaceutical characteristics

  • Mellid Carballal, Rocío
  • Gutiérrez Gutiérrez, Sara
  • Rivas, Carmen
  • García Fuentes, Marcos
Viral protein nanoparticles fill the gap between viruses and synthetic nanoparticles. Combining advantageous properties of both systems, they have revolutionized pharmaceutical research. Virus-like particles are characterized by a structure identical to viruses but lacking genetic material. Another type of viral protein nanoparticles, virosomes, are similar to liposomes but include viral spike proteins. Both systems are effective and safe vaccine candidates capable of overcoming the disadvantages of both traditional and subunit vaccines. Besides, their particulate structure, biocompatibility, and biodegradability make them good candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze viral protein nanoparticles from a pharmaceutical perspective and examine current research focused on their development process, from production to administration. Advances in synthesis, modification and formulation of viral protein nanoparticles are critical so that large-scale production of viral protein nanoparticle products becomes viable and affordable, which ultimately will increase their market penetration in the future. We will discuss their expression systems, modification strategies, formulation, biopharmaceutical properties, and biocompatibility.